Compare ADMA Biologics Inc (ADMA) vs Quanta Services Inc (PWR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Quanta Services Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Quanta Services Inc trades at $663.01 (market cap $98.56B). The key difference: Quanta Services Inc is far larger — about 46.3× ADMA Biologics Inc's market cap, and Quanta Services Inc pays a 0.07% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | PWR | |
|---|---|---|
Market Cap | $2.13B | $98.56B |
Sector | Health | Industrials |
52-Week High | $20.38 | $785.24 |
52-Week Low | $7.60 | $372.50 |
Enterprise Value | $2.20B | $104.51B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Quanta Services (PWR) trades at $656.79, down 1.72% amid bearish technical signals, though it maintains strong analyst support with 27 buy ratings. The company shows robust revenue growth, reaching $28.48B in 2025, with consistent earnings beats in recent quarters. However, premium valuation metrics including a P/E of 92.46 and EV/EBITDA of 39.58 present challenges. Recent news highlights infrastructure demand drivers but questions valuation sustainability after a 79% yearly gain.
PWR's outlook is supported by record backlog and infrastructure spending tailwinds, but execution risks and high valuation create near-term headwinds. The consensus price target of $842.67 suggests 28% upside potential, though investors must weigh growth prospects against current premium multiples and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
